Northwestern Mutual Wealth Management Co. Boosts Position in VanEck Biotech ETF $BBH

Northwestern Mutual Wealth Management Co. lifted its stake in shares of VanEck Biotech ETF (NASDAQ:BBH) by 40,463.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 494,061 shares of the company’s stock after acquiring an additional 492,843 shares during the period. Northwestern Mutual Wealth Management Co. owned 24.83% of VanEck Biotech ETF worth $93,506,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of BBH. Flagship Harbor Advisors LLC purchased a new position in shares of VanEck Biotech ETF during the 4th quarter worth $47,000. Allworth Financial LP increased its position in shares of VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after purchasing an additional 306 shares during the last quarter. Cibc World Market Inc. acquired a new stake in shares of VanEck Biotech ETF during the 3rd quarter worth about $204,000. Focus Financial Network Inc. acquired a new stake in shares of VanEck Biotech ETF during the 4th quarter worth about $206,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of VanEck Biotech ETF during the 3rd quarter worth about $207,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

Shares of NASDAQ:BBH opened at $181.78 on Friday. The business has a 50-day moving average price of $187.28 and a 200 day moving average price of $190.42. VanEck Biotech ETF has a 12-month low of $143.37 and a 12-month high of $202.91.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.